Equillium (EQ) Shares Outstanding (2017 - 2026)
Equillium (EQ) posted quarterly Shares Outstanding (Entity) of $96.3 million for Q1 2026, up 169.54% year-over-year from $35.7 million in Q1 2025, and up 56.64% quarter-over-quarter from $61.5 million in Q4 2025.
Analysis
Equillium (EQ) Shares Outstanding (2017 - 2026) Analysis & Trends
Equillium (EQ) has reported Shares Outstanding (Entity) for 10 consecutive years, with $96.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Shares Outstanding (Entity) rose 169.54% year-over-year to $96.3 million; the TTM figure through Mar 2026 stood at $96.3 million (up 169.54% YoY), while the FY2025 annual figure was $61.5 million, up 72.86% from the prior year.
- Shares Outstanding (Entity) grew to $96.3 million in Q1 2026 per EQ's latest filing, from $61.5 million in the prior quarter.
- Across five years, Shares Outstanding (Entity) topped out at $96.3 million in Q1 2026 and bottomed at $34.3 million in Q1 2022.
- Historically, Shares Outstanding (Entity) has averaged $41.7 million across 5 years, with a median of $35.3 million in 2023.
- Annual changes were most pronounced in 2023 — Shares Outstanding (Entity) grew 0.4% — and 2026, when it surged 169.54%.
- Equillium's Shares Outstanding (Entity) stood at $34.4 million in 2022, then increased by 2.44% to $35.3 million in 2023, then climbed by 0.86% to $35.6 million in 2024, then soared by 72.86% to $61.5 million in 2025, then jumped by 56.64% to $96.3 million in 2026.
- Business Quant data shows EQ's Shares Outstanding (Entity) at $96.3 million in Q1 2026, $61.5 million in Q4 2025, and $60.7 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 61.30 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 398.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 210.89 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 111.58 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 133.61 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 445.06 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 217.35 Mn |
| 10 | Equillium | 249.33 Mn | 249.33 Mn | - | 111.81 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 111.81 Mn |
| Mar 31, 2026 | 96.28 Mn |
| Dec 31, 2025 | 57.30 Mn |
| Sep 30, 2025 | 65.32 Mn |
| Jun 30, 2025 | 35.72 Mn |
| Mar 31, 2025 | 35.59 Mn |
| Dec 31, 2024 | 35.36 Mn |
| Sep 30, 2024 | 35.42 Mn |
| Jun 30, 2024 | 35.29 Mn |
| Mar 31, 2024 | 35.25 Mn |
| Dec 31, 2023 | 34.73 Mn |
| Sep 30, 2023 | 34.88 Mn |
| Jun 30, 2023 | 34.45 Mn |
| Mar 31, 2023 | 34.41 Mn |
| Dec 31, 2022 | 33.73 Mn |
| Sep 30, 2022 | 34.35 Mn |
| Jun 30, 2022 | 34.29 Mn |
| Mar 31, 2022 | 31.87 Mn |
| Dec 31, 2021 | 28.81 Mn |
| Sep 30, 2021 | 29.38 Mn |